Recent clinical study published in Journal of Thoracic Disease supports the combination of Cellvizio with Electromagnetic Navigation Bronchoscopy to...
Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® Formal letter requests...
Q2 2024 Sales Up 48% vs. Q1 but Down 20% Year-on-Year¹ as U.S. Systems Sales Scheduled for the Second Half of 2024 and Temporary Reimbursement...
CellTolerance™ is a unique science-based program designed with physicians and dietitians New data presented at Digestive Disease Week...
Pancreatic cancer remains difficult to diagnose accurately using conventional methods often leading to late-stage diagnoses or unnecessary...
All the resolutions proposed by the Board of Directors were adopted Paris and Boston, June 7, 2024 - 8:00 a.m. CEST - Mauna Kea Technologies...
JV now operational to start selling products in China Paris and Boston, June 6, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth:...
Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award Prestigious international program recognizes...
Paris and Boston, May 21, 2024 - 5:45 p.m. CEST - Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
AI, pancreatic cancer and food intolerance headline wide range of Cellvizio abstracts at gastroenterology’s largest international meeting Paris and...
Paris and Boston, April 30, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Cellvizio utilization continues to expand globally in established and emerging clinical indications Paris and Boston, April 29, 2024 – 5:45 p.m....
